SURPASS

Clinical trial programme of tirzepatide assessing glycaemic control in type 2 diabetes, showing mean HbA1c reductions of between 1.5% and 2.4%.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.